Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Trial Profile

Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HAL03T
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 May 2022 Results assessing safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes published in the BMC Cancer
    • 08 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top